Stage III NSCLC: Practical Application of Immune Checkpoint Inhibition After Chemoradiotherapy

Stage III NSCLC: Practical Application of Immune Checkpoint Inhibition After Chemoradiotherapy

Sunday, April 15, 2018 in Chicago, IL
Dinner -- Hyatt Regency Chicago, 6:30 PM CT
Crystal Ballroom, A


6:30 PM - 7:00 PM Dinner and Registration

7:00 PM - 7:05 PM Welcome and Introduction

7:05 PM - 7:20 PM Background and Rationale for Immune Checkpoint Inhibitors in Unresectable Stage III NSCLC

  • Current standards of care
  • Clinical rationale for immune checkpoint blockade in NSCLC

7:20 PM - 8:05 PM Optimal Integration of Checkpoint Inhibitors Into the Management of Unresectable Stage III NSCLC (Case Discussions)

  • Patient selection
  • Benefits and risks of immunotherapy
  • Management of immune-related toxicities

8:05 PM - 8:20 PM Panel Discussion: Clinical Challenges in Applying New Evidence to Practice in Unresectable Stage III NSCLC

  • Impact on subsequent metastatic disease treatment
  • Future directions

8:20 PM - 8:30 PM Final Thoughts and Audience Question and Answer Session


Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Karen L. Reckamp, MD, MS

Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Victoria Villaflor, MD

Associate Professor of Medicine
Head and Neck Oncology, Thoracic Oncology
Director, Esophageal Cancer
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois


Goal Statement
The goal of this activity is to improve participants’ knowledge of and competence in applying immune checkpoint inhibitors in the treatment of patients with stage III NSCLC.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with stage III non-small-cell lung cancer.

Learning Objectives

  • Discuss the biologic rationale for using immune checkpoint inhibitors in patients with locally advanced NSCLC
  • Plan optimal, individualized therapeutic strategies for patients with stage III NSCLC, considering the available clinical evidence, expert recommendations, and patient preferences
  • Identify subsets of patients most likely to benefit from durvalumab consolidation after definitive platinum-based chemotherapy and concurrent radiation therapy
  • Assess and manage immune-mediated adverse events experienced by patients receiving immune checkpoint inhibitors
  • Explain the benefits and risks of using immune checkpoint inhibitor therapy to patients with unresectable stage III NSCLC


Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of National Comprehensive Cancer Network and Clinical Care Options, LLC. The NCCN is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The National Comprehensive Cancer Network designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement
The National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation
NCCN designates this educational activity for a maximum of 1.5 contact hours.


ACPE logo
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. NCCN designates this knowledge-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credits (Universal Activity Number: 0836-9999-18-055-L01-P).

Attention Pharmacists:

You must complete the post-test and evaluation within 30 days of the activity.  Continuing pharmacy education credit is reported to CPE Monitor once the post-test and evaluation are completed.  Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit can NOT be reported.  If you have not already done so, please complete your e-profile at to obtain your NABP e-Profile ID.

Disclosure of Conflicts of Interest
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Disclosure of Unlabeled Use 
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.